2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol reverses EGF-induced cell migration and invasion through down-regulation of MDM2 in breast cancer cell lines

References


• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Peterse JL, van ‘T Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cance. 2005;5:591–602. doi:10.1038/nrc1670.
   PubMed Web of Science ®Google Scholar
• Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5:402–418. doi:10.1016/j.apsb.2015.07.005.
   PubMed Web of Science ®Google Scholar
• Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell. 2013;23:573–581. doi:10.1016/j.ccr.2013.04.017.
   PubMed Web of Science ®Google Scholar
• Welch DR, Steeg PS, Rinker-Schaeffer CW. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res. 2000;2:408–416.
   PubMed Web of Science ®Google Scholar
• Radisky DC. Epithelial-mesenchymal transition. J Cell Sci. 2005;118:4325–4326. doi:10.1242/jcs.02552.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–142. doi:10.1038/nrm1835.
   PubMed Web of Science ®Google Scholar
• Bartis D, Mise N, Mahida RY, Eickelberg O, Thickett DR. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? Thorax. 2014;69:760–765. doi:10.1136/thoraxjnl-2013-204608.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–890. doi:10.1158/0008-5472.CAN-07-0575.
   PubMed Web of Science ®Google Scholar
• Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung M-C. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007;67:9066–9076. doi:10.1158/0008-5472.CAN-07-0575.
   PubMed Web of Science ®Google Scholar
• Olsen DA, Bechmann T, Ostergaard B, Wamberg PA, Jakobsen EH, Brandslund I. Increased concentrations of growth factors and activation of the EGFR system in breast cancer. Clin Chem Lab Med. 2012;50:1809–1818. doi:10.1515/cclm-2011-0823.
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927–939. doi:10.1016/j.cell.2004.06.006.
   PubMed Web of Science ®Google Scholar
• Fu J, Qin L, He T, Qin J, Hong J, Wong J, Liao L, Xu J. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res. 2011;21:275–289. doi:10.1038/cr.2010.118.
   PubMed Web of Science ®Google Scholar
• Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, Hudson LG. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 2001;61:1855–1861. PMID: 11280738.
   PubMed Web of Science ®Google Scholar
• Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003;4:657–665. doi:10.1038/nrm1175.
   PubMed Web of Science ®Google Scholar
• Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang X-H, Du J, Liu Y-X, Sun B-C. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology (Baltimore, Md). 2010;51:545–556. doi:10.1002/hep.23311.
   PubMed Web of Science ®Google Scholar
• Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, Yang J. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011;19:372–386. doi:10.1016/j.ccr.2011.01.036.
   PubMed Web of Science ®Google Scholar
• Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K, Takano Y. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26:3579–3583. PMID: 17094486.
   PubMed Web of Science ®Google Scholar
• Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DC, Adams SE, Gearing AJ. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol. 1997;72:155–161. PMID: 9042108.
   PubMed Web of Science ®Google Scholar
• Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cance. 2002;2:657–672. doi:10.1038/nrc884.
   PubMed Web of Science ®Google Scholar
• Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO,Huntsman DG, Gilks CB. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Modern pathology: an official journal of the United States and Canadian. Acad Pathology. 2006;19:69–74. doi:10.1038/modpathol.3800484.
   Google Scholar
• Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5:27–41. PMID: 15720187.
   PubMed Web of Science ®Google Scholar
• Rayburn ER, Ezell SJ, Zhang R. Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med Chem. 2009;9:882–903. PMID: 19538162.
   PubMed Web of Science ®Google Scholar
• Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin C-W, Yang S-C, Chan W-K, et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol. 2009;11:694–704. doi:10.1038/ncb1875.
   PubMed Web of Science ®Google Scholar
• Lin TY, Hsu HY. Ling Zhi-8 reduces lung cancer mobility and metastasis through disruption of focal adhesion and induction of MDM2-mediated Slug degradation. Cancer Lett. 2016;375:340–348. doi:10.1016/j.canlet.2016.03.018.
   PubMed Web of Science ®Google Scholar
• Polanski R, Warburton HE, Ray-Sinha A, Devling T, Pakula H, Rubbi CP, Vlatković N, Boyd MT. MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism. FEBS Lett. 2010;584:4695–4702. doi:10.1016/j.febslet.2010.10.049.
   PubMed Web of Science ®Google Scholar
• Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989;45:209–211. PMID: 2920809.
   PubMedGoogle Scholar
• Kanthou C, Tozer GM. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets. 2007;11:1443–1457. doi:10.1517/14728222.11.11.1443.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cance. 2005;5:423–435. doi:10.1038/nrc1628.
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol. 2009;90:284–294. doi:10.1111/j.1365-2613.2009.00651.x.
   PubMed Web of Science ®Google Scholar
• Mahal K, Biersack B, Caysa H, Schobert R, Mueller T. Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. Invest New Drugs. 2015;33:541–554. doi:10.1007/s10637-015-0215-9.
   PubMed Web of Science ®Google Scholar
• Xu J, Zuo D, Qi H, Shen Q, Bai Z, Han M, Li Z, Zhang W, Wu Y. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ0814061), a novel microtubule inhibitor, evokes G2/M cell cycle arrest and apoptosis in human breast cancer cells. Biomed Pharmacother. 2016;78:308–321. doi:10.1016/j.biopha.2016.01.040.
   PubMed Web of Science ®Google Scholar
• Xu J, Han M, Shen J, Guan Q, Bai Z, Lang B, Zhang H, Li Z, Zuo D, Zhang W, et al. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway. Cancer Lett. 2016;383:9–17. doi:10.1016/j.canlet.2016.09.011.
   PubMed Web of Science ®Google Scholar
• Hardy KM, Booth BW, Hendrix MJ, Salomon DS, Strizzi L. ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:191–199. doi:10.1007/s10911-010-9172-2.
   PubMed Web of Science ®Google Scholar
• Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–149. doi:10.1016/j.pharmthera.2014.10.001.
   PubMed Web of Science ®Google Scholar
• Sun L, Fang J. Epigenetic regulation of epithelial-mesenchymal transition. Cell Mol Life Sci. 2016;73:4493–4515. doi:10.1007/s00018-016-2303-1.
   PubMed Web of Science ®Google Scholar
• Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 1997;11:1974–1986. PMID: 9271120. doi:10.1101/gad.11.15.1974.
   PubMed Web of Science ®Google Scholar
• Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000;2:569–573. doi:10.1038/35023507.
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–299. doi:10.1038/387296a0.
   PubMed Web of Science ®Google Scholar
• Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, Fischer P, McInnes C, Barlow PN. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol. 2005;350:587–598. doi:10.1016/j.jmb.2005.05.010.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (New York, NY). 2004;303:844–848. PMID: 18051440. doi:10.1126/science.1092472.
   Google Scholar
• Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res. 2003;1:993–1000.
   PubMed Web of Science ®Google Scholar
• Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420:25–27. PMID: 9450543.
   PubMed Web of Science ®Google Scholar
• Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P, Mannermaa A, Kosma V-M. Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer. 2011;11:73. doi:10.1186/1471-2407-11-73.
   PubMed Web of Science ®Google Scholar
• Qin L, Liu Z, Chen H, Xu J. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res. 2009;69:3819–3827. doi:10.1158/0008-5472.CAN-08-4389.
   PubMed Web of Science ®Google Scholar
• Vernon AE, LaBonne C. Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol. 2004;14:R719–21. doi:10.1016/j.cub.2004.08.048.
   PubMed Web of Science ®Google Scholar
• Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biol Ther. 2004;3:1058–1059. PMID: 15640618. doi:10.4161/cbt.3.11.1302.
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res. 2006;66:4549–4552. doi:10.1158/0008-5472.CAN-05-3850.
   PubMed Web of Science ®Google Scholar
• Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, Zanatta L, Pivetta F, Grizzo A, Sonego M, et al. A “twist box” code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer Cell. 2012;22:404–415. doi:10.1016/j.ccr.2012.08.003.
   PubMed Web of Science ®Google Scholar
• Qin Q, Xu Y, He T, Qin C, Xu J. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 2012;22:90–106. doi:10.1038/cr.2011.144.
   PubMed Web of Science ®Google Scholar